57th ASH Annual Meeting and Exposition (December 5-8, 2015): 634. Myeloproliferative Syndromes: Clinical: Combination Therapy in MPN

Myeloproliferative Syndromes: Clinical Oral and Poster Abstracts
Oral

W315, Level 3 (Orange County Convention Center)

Moderators:

Alison Moliterno, MD, Johns Hopkins University School of Medicine and Laura C. Michaelis, MD, Medical College of Wisconsin

Disclosures:

Michaelis: Incyte: Membership on an entity’s Board of Directors or advisory committees ; CTI Biopharma: Membership on an entity’s Board of Directors or advisory committees ; Wyeth: Membership on an entity’s Board of Directors or advisory committees ; Pfizer: Equity Ownership .

4:30 PM

823

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

Naval Daver, MD¹, Guillermo Garcia-Manero, MD², Jorge E. Cortes, MD³, Lingsha Zhou⁴^*, Sherry Pierce, BSN, BA³^*, Naveen Pemmaraju, MD³, Elias Jabbour³, Courtney DiNardo, MD³, Tapan Kadia, MD³, Gautam Borthakur, MD³, Farhad Ravandi, MD³, Marina Konopleva, MD, PhD⁵, Franklin Wynn⁶^*, Stephanie Van Derbur⁶^*, Zeev Estrov, MD³, Hagop M. Kantarjian, MD³ and Srdan Verstovsek, MD³

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, TX
²Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
⁵Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶The University of Texas M. D. Anderson Cancer Center, Houston, TX

4:45 PM

824

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Stine Ulrik Mikkelsen, MD¹^*, Lasse Kjær, MSc, PhD¹^*, Vibe Skov, MSc, PhD¹^*, Mads Emil Bjørn, MD, PhD Student¹^*, Christen Lykkegaard Andersen, MD, PhD²^*, Ole Weis Bjerrum, MD, DMSc²^*, Nana Brochmann, MD, PhD Student¹^*, Daniel El Fassi, MD, PhD³^*, Torben A Kruse, Professor, PhD⁴^*, Thomas Stauffer Larsen, MD, PhD⁵^*, Torben Mourits-Andersen, MD⁶^*, Claus Henrik Nielsen, MD, Professor, DMSc⁷^*, Niels Pallisgaard, MSc⁸^*, Mads Thomassen, MSc, PhD⁴^* and Hans Carl Hasselbalch, MD, Professor, DMSc¹

¹Department of Hematology, Roskilde University Hospital, Roskilde, Denmark
²Department of Hematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
³Department of Hematology, Herlev University Hospital, Copenhagen, Denmark
⁴Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark
⁵Department of Hematology, Odense University Hospital, Odense, Denmark
⁶Department of Hematology, Sydvestjysk Hospital, Esbjerg, Denmark
⁷Institute for Inflammation Research, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
⁸Department of Pathology, Roskilde University Hospital, Roskilde, Denmark

5:00 PM

825

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD, FRCP, FRCPath¹, Claire N. Harrison², Hans Hasselbalch, MD³, Lisa Pieri, MD, PhD⁴^*, Steffen Koschmieder, MD⁵, Francisco Cervantes⁶, Weichao Bao, PhD⁷^*, Stacey Kalambakas, MD⁷^*, Edric Atienza, MSHS⁷^*, Prashanth Gopalakrishna, MBBS, MRCS⁸^* and Florian H. Heidel, MD⁹

¹Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
²Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
³Department of Hematology, Roskilde University Hospital, Roskilde, Denmark
⁴Azienda Ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy
⁵RWTH Aachen University Hospital, Aachen, Germany
⁶Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
⁸Novartis Pharma AG, Basel, Switzerland
⁹Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

5:15 PM

826

A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis

Frank Stegelmann, MD¹^*, Markus Bangerter, MD²^*, Florian H Heidel, MD³, Martin Griesshammer, MD⁴^*, Holger Hebart, MD⁵, Andreas Hochhaus, MD⁶, Steffen Koschmieder, MD⁷, Robert Möhle, MD⁸, Andreas Reiter, MD⁹^*, Christof Scheid¹⁰, Rebecca Kirschbaum¹¹^*, Regina Reim¹¹^*, Ulrike Sutter¹¹^*, Katrin Vetter¹¹^*, Hartmut Döhner, MD¹¹^*, Richard F. Schlenk, MD¹² and Konstanze Döhner, MD¹¹

¹Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
²Hematology and Oncology Practice, Augsburg, Germany
³Otto-von-Guericke University Medical Center Magdeburg, Magdeburg, Germany
⁴Department of Hematology/Oncology, Klinikum Minden, Minden, Germany
⁵Department of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany
⁶Department of Haematology and Medical Oncology, Department of Internal Medicine II, University Hospital Jena, Jena, Germany
⁷Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany
⁸Department of Hematology and Oncology, University Tübingen, Tübingen, Germany
⁹Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
¹⁰University of Cologne, Cologne, Germany
¹¹Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
¹²University Hospital of Ulm, Ulm, Germany

5:30 PM

827

An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study

Simon T Durrant¹, Arnon Nagler²^*, Alessandro M Vannucchi³^*, David Lavie, MD⁴^*, Charles Chuah⁵, Francesco Passamonti⁶^*, Heinz Gisslinger, MD⁷, Philipp le Coutre⁸^*, Prashanth Gopalakrishna, MBBS, MRCS⁹^*, Bruyère Mahuzier¹⁰^*, Shuyuan Mo¹¹^* and Joaquin Martinez-Lopez¹²^*

¹Royal Brisbane Hospital, Herston, Australia
²The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
³University of Florence, Florence, Italy
⁴Department of Hematology and Bone Marrow Transplantation, Hebrew University-Hadassah Medical Organization, Jerusalem, Israel
⁵Department of Hematology, Singapore General Hospital, Singapore, Singapore
⁶Ospedale di Circolo e Fondazione Macchi, Varese, Italy
⁷Medical University of Vienna, Vienna, Austria
⁸Schumannstr, Medizinische Klinik m. S. Hämatologie und Onkologi, Berlin, Germany
⁹Novartis Pharma AG, Basel, Switzerland
¹⁰Novartis Pharma S.A.S, Rueil-Malmaison, France
¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
¹²Hospital-12-de-Octubre, Madrid, Spain

5:45 PM

828

ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis

Animesh Pardanani, MBBS, PhD¹, Terra L. Lasho, PhD²^*, Christy Finke, BS²^*, Darci Zblewski, CNP²^*, Ramy Abdelrahman, M.B., B.Ch.²^*, Emnet Wassie, M.D.²^*, Naseema Gangat, MBBS², Curtis A. Hanson, MD³, Rhett P. Ketterling, MD⁴^* and Ayalew Tefferi, MD²

¹Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Division of Hematopathology, Mayo Clinic, Rochester, MN
⁴Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

See more of: Myeloproliferative Syndromes: Clinical
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

634.O3.6 634. Myeloproliferative Syndromes: Clinical: Combination Therapy in MPN